Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells

Cancer Science

Volumn 102, Issue 1, 2011, Pages 111-116

  Koshikawa, Naohiko ^a   Mizushima, Hiroto ^b   Minegishi, Tomoko ^a   Eguchi, Fuyuki ^c   Yotsumoto, Fusanori ^d   Nabeshima, Kazuki ^d   Miyamoto, Shingo ^d   Mekada, Eisuke ^b   Seiki, Motoharu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c ASO IIZUKA HOSPITAL   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERSTITIAL COLLAGENASE;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; ASCITES; CANCER CELL; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; OVARY CARCINOMA; OVARY METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

CELL LINE, TUMOR; COLLAGEN; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASE 14; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS;

EID: 78650182619     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01748.x     Document Type: Article

References (24)

1. Penson RT, Shannon KE, Sharpless NE, Seiden MV. Ovarian cancer: an update on genetics and therapy. Compr Ther 1998; 24: 477-87.
2. Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001; 28: 67-79.
3. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007; 25: 4057-65.
4. Miyamoto S, Fukami T, Yagi H, Kuroki M, Yotsumoto F. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. Anticancer Res 2009; 29: 823-30.
5. Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci 2006; 97: 341-7.
6. Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1997; 1333: F179-99.
7. Higashiyama S, Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta 2005; 1751: 110-7.
8. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci 2008; 99: 214-20.
9. Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 2002; 16: 307-23.
10. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006; 231: 20-7.
11. Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular micro-environment. J Cell Physiol 2006; 206: 1-8.
12. Koshikawa N, Mizushima H, Minegishi T, Iwamoto R, Mekada E, Seiki M. MT1-MMP cleaves off the NH2-terminal portion of HB-EGF and converts it into a heparin-independent growth factor. Cancer Res 2010; 70: 6093-103.
13. Takazaki R, Shishido Y, Iwamoto R, Mekada E. Suppression of the biological activities of the epidermal growth factor (EGF)-like domain by the heparin-binding domain of heparin-binding EGF-like growth factor. J Biol Chem 2004; 279: 47335-43.
14. Koshikawa N, Minegishi T, Nabeshima K, Seiki M. Development of a new tracking tool for the human monomeric laminin-gamma 2 chain in vitro and in vivo. Cancer Res 2008; 68: 530-6.
15. Tanaka Y, Miyamoto S, Suzuki SO et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005; 11: 4783-92.
16. Davidson B, Goldberg I, Berner A et al. Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol 2001; 115: 517-24.
17. Harding PA, Davis-Fleischer KM, Crissman-Combs MA, Miller MT, Brigstock DR, Besner GE. Induction of anchorage independent growth by heparin-binding EGF-like growth factor (HB-EGF). Growth Factors. 1999; 17: 49-61.
18. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003; 194: 1-11.
19. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003; 114: 33-45.
20. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006; 25: 115-36.
21. Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol 2009; 185: 11-9.
22. Yagi H, Yotsumoto F, Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther. 2008; 7: 3441-51.
23. Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E, Miyamoto S. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 2009; 124: 1429-39.
24. Nakagawa T, Higashiyama S, Mitamura T, Mekada E, Taniguchi N. Amino-terminal processing of cell surface heparin-binding epidermal growth factor-like growth factor up-regulates its juxtacrine but not its paracrine growth factor activity. J Biol Chem 1996; 271: 30858-63.